Brief: Tarsus Pharmaceuticals Initiates Phase 2A Ersa Trial Evaluating Tp-03 For The Treatment Of Meibomian Gland Disease
05/08/2022 15:03
Aug 5 (Reuters) - Tarsus Pharmaceuticals Inc TARS.O :
* TARSUS INITIATES PHASE 2A ERSA TRIAL EVALUATING TP-03 FOR
THE
TREATMENT OF MEIBOMIAN GLAND DISEASE
* TARSUS PHARMACEUTICALS INC- PLANS TO SUBMIT A NEW DRUG
APPLICATION (NDA) TO FDA FOR TP-03 FOR TREATMENT OF DEMODEX
BLEPHARITIS IN SECOND HALF OF 2022
Source text for Eikon: ID:nGNX5BPgH9
Further company coverage: TARS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)